Greenleaf Trust Has $234,000 Position in Moderna, Inc. (NASDAQ:MRNA)

Greenleaf Trust cut its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 35.1% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,505 shares of the company’s stock after selling 1,894 shares during the period. Greenleaf Trust’s holdings in Moderna were worth $234,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC acquired a new position in shares of Moderna in the second quarter worth $26,000. Cedar Wealth Management LLC increased its position in Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the last quarter. Westside Investment Management Inc. purchased a new stake in shares of Moderna during the 1st quarter worth about $32,000. Family Firm Inc. acquired a new stake in shares of Moderna during the 2nd quarter valued at about $33,000. Finally, Bank & Trust Co bought a new stake in shares of Moderna in the 2nd quarter valued at approximately $36,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

MRNA opened at $53.09 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The firm’s fifty day moving average price is $67.68 and its two-hundred day moving average price is $102.77. Moderna, Inc. has a 1 year low of $52.26 and a 1 year high of $170.47. The company has a market capitalization of $20.41 billion, a price-to-earnings ratio of -3.45 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna’s quarterly revenue was down 29.9% compared to the same quarter last year. During the same period last year, the company posted ($3.62) earnings per share. As a group, analysts anticipate that Moderna, Inc. will post -9.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Royal Bank of Canada reiterated a “sector perform” rating and set a $75.00 price target on shares of Moderna in a report on Thursday, September 19th. Hsbc Global Res raised Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and dropped their price target for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. HSBC raised Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective for the company in a report on Wednesday, August 28th. Finally, Sanford C. Bernstein assumed coverage on Moderna in a report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $94.65.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 715 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $119.96, for a total value of $1,799,400.00. Following the transaction, the director now directly owns 2,224,015 shares in the company, valued at approximately $266,792,839.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,184 shares of company stock worth $2,037,931 over the last quarter. 15.70% of the stock is currently owned by company insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.